Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Imugene Limited ( (AU:IMU) ) has provided an announcement.
Imugene Limited announced the cessation of a total of 3,439,132 restricted stock units due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure and could influence investor perception regarding the company’s operational progress and strategic direction.
More about Imugene Limited
Imugene Limited operates in the biotechnology industry, focusing on the development of novel therapies that activate the immune system of cancer patients to treat and eradicate tumors. The company is engaged in advancing a range of immunotherapy products, with a market focus on enhancing the effectiveness of cancer treatment.
YTD Price Performance: 25.00%
Average Trading Volume: 136,155
Technical Sentiment Signal: Strong Buy
Current Market Cap: $111.8M
See more data about IMU stock on TipRanks’ Stock Analysis page.